1-3 of 3
Petro E. Petrides, MD, PhD
Close
Sort by
Journal Articles

Final Results from the Phase 3 Traial Areta Comparing a Novel, Extended-Release Anagrelide Formulation to Placebo in Essential Thrombocythemia Patients with Defined Risk Status

Heinz Gisslinger, MD, Christoph Klade, Kudrat Abdulkadyrov, MD, Slawomira Kyrcz-Krzemien, MD PhD, Elena Karyagina, MD, Anait L. Melikyan, MD PhD, Krzysztof Warzocha, Barbara Grohmann-Izay, MD, Juri Hodisch, MD, Rudolf S. Widmann, PhD BSc, Robert Kralovics, Petro E. Petrides, MD PhD, Jiri Schwarz, MD PhD, Jean-Jacques Kiladjian, MD PhD
Journal: Blood
Blood (2016) 128 (22): 476.
https://doi.org/10.1182/blood.V128.22.476.476
Published: 2016
Journal Articles

Sub-Optimal Inhibition of Thrombus Formation by Aspirin (as measured by RTTP analysis) In Primary Thrombocythemia

Gillian Stephens, Ph.D., Jan Tauscher, M.D., Fabian Siegel, M.D., David R. Phillips, PhD, Patrick Andre, Ph.D., Petro E. Petrides, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 4218.
https://doi.org/10.1182/blood.V116.21.4218.4218
Published: 2010
Journal Articles

Bleeding Risk in Patients with Essential Thrombocythemia and a Platelet Count of More Than 1.5 Million/μl: A Challenge of the Dogma of Mandatory Initiation of Cytoreductive Therapy.

Petro E. Petrides, MD, PhD, Fabian Siegel
Journal: Blood
Blood (2007) 110 (11): 4660.
https://doi.org/10.1182/blood.V110.11.4660.4660
Published: 2007